This drug delayed rheumatoid arthritis for years after treatment ended — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Abatacept administered for 12 months delayed rheumatoid arthritis onset by up to four years compared with placebo.
- The Lancet Rheumatology published the follow‑up analysis, which tracked 213 high‑risk participants from the UK and Netherlands for four to eight years.
- Professor Andrew Cope of King's College London led the study, noting that early intervention can provide lasting symptom relief and postpone disease even after treatment stops.
- Rheumatoid arthritis currently lacks any approved preventive therapy for high‑risk individuals, affecting about half a million people in the UK.
Why it matters: High‑risk patients gain years of symptom‑free life, reducing disability and healthcare costs, while insurers and employers see lower long‑term expenses, easing the burden on the NHS and improving workforce participation.
Ask SkimNews
